Itaspor-SB 130mg Capsule contains Itraconazole, a broad-spectrum triazole antifungal agent indicated for the treatment of various fungal infections. Itraconazole exerts its antifungal activity by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Itaspor-SB is commonly prescribed for the management of systemic and superficial mycoses, including blastomycosis, histoplasmosis, aspergillosis, and onychomycosis, as well as infections caused by dermatophytes and yeasts such as Candida species. The capsule formulation allows for oral administration, with absorption enhanced when taken with food. Dosage and duration of therapy depend on the type and severity of infection, patient response, and clinical judgment. It is important to monitor liver function during prolonged therapy due to potential hepatotoxicity. Caution is advised in patients with hepatic impairment or congestive heart failure. Itaspor-SB may interact with several medications by inhibiting cytochrome P450 enzymes, necessitating careful evaluation of concomitant drug use. Adverse effects may include gastrointestinal disturbances, headache, rash, and, rarely, hepatotoxicity. Patients should adhere to prescribed dosing and consult healthcare providers if adverse reactions occur or symptoms persist.